• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Acinetobacter Infections - Pipeline Review, H2 2012 Product Image

Acinetobacter Infections - Pipeline Review, H2 2012

  • Published: November 2012
  • 44 pages
  • Global Markets Direct

Acinetobacter Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Acinetobacter Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Acinetobacter Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acinetobacter Infections. Acinetobacter Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acinetobacter Infections.
- A review of the Acinetobacter Infections products under development READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Acinetobacter Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Acinetobacter Infections 7
Acinetobacter Infections Therapeutics under Development by Companies 9
Discovery and Pre-Clinical Stage Products 11
Comparative Analysis 11
Acinetobacter Infections Therapeutics – Products under Development by Companies 12
Companies Involved in Acinetobacter Infections Therapeutics Development 13
Rib-X Pharmaceuticals, Inc. 13
Achaogen Inc. 14
Evolva SA 15
Kenta Biotech Ltd. 16
NanoBio Corporation 17
SelectX Pharmaceuticals, Inc. 18
Trana Discovery, Inc. 19
Cantab Biopharmaceuticals Limited 20
Acinetobacter Infections – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
KBAB-401 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RX-04 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Expanded-Spectrum Aminoglycosides Development Program - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SLP-0907 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 30
EV-035 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Gram-Negative Programme - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ACHN-978 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Carbavance - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
NB-401 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SXP-2554 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Acinetobacter Infections Therapeutics – Drug Profile Updates 38
Acinetobacter Infections Therapeutics - Dormant Products 40
Acinetobacter Infections – Product Development Milestones 41
Featured News & Press Releases 41
Oct 15, 2009: NanoBio’s Nanoemulsion Kills Drug-Resistant Bacteria Found In Cystic Fibrosis Patients 41
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Number of Products Under Development for Acinetobacter Infections, H2 2012 7
Products under Development for Acinetobacter Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 10
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Rib-X Pharmaceuticals, Inc., H2 2012 13
Achaogen Inc., H2 2012 14
Evolva SA, H2 2012 15
Kenta Biotech Ltd., H2 2012 16
NanoBio Corporation, H2 2012 17
SelectX Pharmaceuticals, Inc., H2 2012 18
Trana Discovery, Inc., H2 2012 19
Cantab Biopharmaceuticals Limited, H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Acinetobacter Infections Therapeutics – Drug Profile Updates 38
Acinetobacter Infections Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Acinetobacter Infections, H2 2012 7
Products under Development for Acinetobacter Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Discovery and Pre-Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos